🏥 治験ポータル

← 治験一覧に戻る

標準リスクの小児再発性ALLの治療に関する国際研究2010

基本情報

NCT ID: NCT01802814
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 700
治験依頼者名: Charite University, Berlin, Germany

概要

The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set up a large international study group platform allowing for optimization of standard treatment strategies and integration of new agents.

対象疾患

Acute Lymphoblastic Leukemia (ALL)

介入

SR-A + Epratuzumab(DRUG)

SR-B + Epratuzumab(DRUG)

依頼者（Sponsor）

University Children's Hospital, Zurich(OTHER)

University Hospital, Motol(OTHER)

Prinses Máxima Centrum (Co-sponsor Netherlands)(UNKNOWN)

Instituto Português De Oncologia De Lisboa (Co-sponsor Lisboa)(UNKNOWN)

National Hospital Organization Nagoya Medical Center (Co-sponsor Japan)(UNKNOWN)

Copenhagen University Hospital (Rigshospitalet) (Co-sponsor Copenhagen)(UNKNOWN)

Oslo University Hospital (Co-sponsor Oslo)(UNKNOWN)

European Organisation For Research And Treatment Of Cancer - Eortc(NETWORK)

St. Anna Kinderkrebsforschung (Co-sponsor Austria)(UNKNOWN)

Tel Aviv Sourasky Medical Centre (Co-sponsor Israel)(UNKNOWN)

Charite University, Berlin, Germany(OTHER)

Spanish Society Of Pediatric Hematology And Oncology (Sehop) (Co-sponsor Spain)(UNKNOWN)

Turku University (Co-sponsor Finland)(UNKNOWN)

Centre Hospitalier Universitaire De Nice(OTHER)

Australian & New Zealand Children's Haematology/oncology Group(OTHER)

Our Lady's Chilrden's Hospital (Co-sponsor Ireland)(UNKNOWN)

Ospedale Pediatrico Bambino Gesù (Co-sponsor Italy)(UNKNOWN)

Central Manchester University (Co-sponsor United Kingdom)(UNKNOWN)

Medical University Of Wroclaw (Co-sponsor Poland)(UNKNOWN)

実施施設 (1)

聖路加国際病院

Tokyo, Japan